TY - JOUR
T1 - Depression, anxiety, and post-traumatic stress disorder symptoms after hyperemesis gravidarum
T2 - a prospective cohort study
AU - Nijsten, Kelly
AU - van der Minnen, Loïs M
AU - Dean, Caitlin
AU - Bais, Joke M J
AU - Ris-Stalpers, Carrie
AU - van Eekelen, Rik
AU - Bremer, Henk A
AU - van der Ham, David P
AU - Heidema, Wieteke M
AU - Huisjes, Anjoke
AU - Kleiverda, Gunilla
AU - Kuppens, Simone M
AU - van Laar, Judith O E H
AU - Langenveld, Josje
AU - van der Made, Flip
AU - Papatsonis, Dimitri
AU - Pelinck, Marie-José
AU - Pernet, Paula J
AU - van Rheenen-Flach, Leonie
AU - Rijnders, Robbert J
AU - Scheepers, Hubertina C J
AU - Vogelvang, Tatjana
AU - Mol, Ben W
AU - Olff, Miranda
AU - Roseboom, Tessa J
AU - Koot, Marjette H
AU - Grooten, Iris J
AU - Painter, Rebecca C
N1 - Funding Information: The MOTHER study was supported by a research grant from the North West Hospital Group, Alkmaar, The Netherlands under grant number 2013T085. The follow-up study was supported by the Amsterdam Reproduction and Development (AR&D) Research Institute, Amsterdam UMC, The Netherlands under project number 23346. Neither funders had any role in the planning, execution or interpretation of this study. The authors thank all participating women in both the MOTHER and follow-up study. Funding Information: Dr B.W. Mol reports grants from NHMRC outside the submitted work. Dr R.C. Painter reports grants from Amsterdam Reproduction and Development, during the conduct of the study, and she is the clinical and scientific advisor to the Dutch patient organization for Hyperemesis Gravidarum. She was also the chair of the organizing committee for the 3rd International Collaboration on Hyperemesis Gravidarum conference, Amsterdam, October 2019. Drs K. Nijsten and all other authors report no conflict of interests. ICMJE disclosure of interest forms are submitted as supporting information . Publisher Copyright: © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - OBJECTIVE: To determine the prevalence of depression, anxiety, and posttraumatic stress disorder (PTSD) years after hyperemesis gravidarum (HG) and its association with HG severity.MATERIAL AND METHODS: This prospective cohort study consisted of a follow-up of 215 women admitted for HG, who were eligible to participate in a randomized controlled trial and either declined or agreed to be randomized between 2013 and 2016 in 19 hospitals in the Netherlands. Participants completed the Hospital Anxiety and Depression Scale (HADS) six weeks postpartum and during follow-up and the PTSD checklist for DSM-5 (PCL-5) during follow-up. An anxiety or depression score ≥8 is indicative of an anxiety or depression disorder and a PCL-5 ≥ 31 indicative of PTSD. Measures of HG severity were symptom severity (PUQE-24: Pregnancy Unique Quantification of Emesis), weight change, duration of admissions, readmissions, and admissions after the first trimester.RESULTS: About 54/215 participants completed the HADS six weeks postpartum and 73/215 participants completed the follow-up questionnaire, on average 4.5 years later. Six weeks postpartum, 13 participants (24.1%) had an anxiety score ≥8 and 11 participants (20.4%) a depression score ≥8. During follow-up, 29 participants (39.7%) had an anxiety score ≥8, 20 participants (27.4%) a depression score ≥8, and 16 participants (21.9%) a PCL-5 ≥ 31.Multivariable logistic regression analysis showed that for every additional point of the mean PUQE-24 three weeks after inclusion, the likelihood of having an anxiety score ≥8 and PCL-5 ≥ 31 at follow-up increased with OR 1.41 (95% CI: 1.10;1.79) and OR 1.49 (95% CI: 1.06;2.10) respectively.CONCLUSION: Depression, anxiety, and PTSD symptoms are common years after HG occurred.
AB - OBJECTIVE: To determine the prevalence of depression, anxiety, and posttraumatic stress disorder (PTSD) years after hyperemesis gravidarum (HG) and its association with HG severity.MATERIAL AND METHODS: This prospective cohort study consisted of a follow-up of 215 women admitted for HG, who were eligible to participate in a randomized controlled trial and either declined or agreed to be randomized between 2013 and 2016 in 19 hospitals in the Netherlands. Participants completed the Hospital Anxiety and Depression Scale (HADS) six weeks postpartum and during follow-up and the PTSD checklist for DSM-5 (PCL-5) during follow-up. An anxiety or depression score ≥8 is indicative of an anxiety or depression disorder and a PCL-5 ≥ 31 indicative of PTSD. Measures of HG severity were symptom severity (PUQE-24: Pregnancy Unique Quantification of Emesis), weight change, duration of admissions, readmissions, and admissions after the first trimester.RESULTS: About 54/215 participants completed the HADS six weeks postpartum and 73/215 participants completed the follow-up questionnaire, on average 4.5 years later. Six weeks postpartum, 13 participants (24.1%) had an anxiety score ≥8 and 11 participants (20.4%) a depression score ≥8. During follow-up, 29 participants (39.7%) had an anxiety score ≥8, 20 participants (27.4%) a depression score ≥8, and 16 participants (21.9%) a PCL-5 ≥ 31.Multivariable logistic regression analysis showed that for every additional point of the mean PUQE-24 three weeks after inclusion, the likelihood of having an anxiety score ≥8 and PCL-5 ≥ 31 at follow-up increased with OR 1.41 (95% CI: 1.10;1.79) and OR 1.49 (95% CI: 1.06;2.10) respectively.CONCLUSION: Depression, anxiety, and PTSD symptoms are common years after HG occurred.
KW - Hyperemesis gravidarum
KW - anxiety disorder
KW - depression disorder
KW - postpartum depression
KW - posttraumatic stress disorder
UR - http://www.scopus.com/inward/record.url?scp=85132753101&partnerID=8YFLogxK
U2 - https://doi.org/10.1080/14767058.2022.2089550
DO - https://doi.org/10.1080/14767058.2022.2089550
M3 - Article
C2 - 35726837
SN - 1476-7058
VL - 35
SP - 10055
EP - 10063
JO - Journal of Maternal-Fetal and Neonatal Medicine
JF - Journal of Maternal-Fetal and Neonatal Medicine
IS - 25
ER -